Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1094

1.

Clinicopathologic Features of a Series of Primary Renal CIC-rearranged Sarcomas With Comprehensive Molecular Analysis.

Mangray S, Kelly DR, LeGuellec S, Fridman E, Aggarwal S, Shago M, Matoso A, Madison R, Pramanik S, Zhong S, Li R, Lombardo KA, Cramer S, Pressey J, Ross JS, Corona RJ, Bratslavsky G, Argani P, Coindre JM, Somers GR, Ali SM, Yakirevich E.

Am J Surg Pathol. 2018 Jun 12. doi: 10.1097/PAS.0000000000001098. [Epub ahead of print]

PMID:
29901569
2.

Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling.

Tarlock K, Zhong S, He Y, Ries R, Severson E, Bailey M, Morley S, Balasubramanian S, Erlich R, Lipson D, Otto GA, Vergillo JA, Kolb EA, Ross JS, Mughal T, Stephens PJ, Miller V, Meshinchi S, He J.

Oncotarget. 2018 May 29;9(41):26417-26430. doi: 10.18632/oncotarget.25443. eCollection 2018 May 29.

3.

Quantifying the utilization of medical devices necessary to detect postmarket safety differences: A case study of implantable cardioverter defibrillators.

Bates J, Parzynski CS, Dhruva SS, Coppi A, Kuntz R, Li SX, Marinac-Dabic D, Masoudi FA, Shaw RE, Warner F, Krumholz HM, Ross JS.

Pharmacoepidemiol Drug Saf. 2018 Jun 12. doi: 10.1002/pds.4565. [Epub ahead of print]

PMID:
29896873
4.

Receptor Tyrosine Kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors.

Schrock AB, Zhu VW, Hsieh WS, Madison R, Creelan B, Silberberg J, Costin D, Bharne A, Bonta I, Bosemani T, Nikolinakos P, Ross JS, Miller VA, Ali SM, Klempner SJ, Ignatius Ou SH.

J Thorac Oncol. 2018 Jun 5. pii: S1556-0864(18)30674-9. doi: 10.1016/j.jtho.2018.05.027. [Epub ahead of print]

5.

The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements.

Wallach JD, Ross JS, Naci H.

Clin Trials. 2018 Jun;15(3):219-229. doi: 10.1177/1740774518770648.

PMID:
29871509
6.

The US Food and Drug Administration's expedited approval programs: Addressing premarket flexibility with enhanced postmarket evidence generation.

Wallach JD, Ross JS, Naci H.

Clin Trials. 2018 Jun;15(3):243-246. doi: 10.1177/1740774518770657. No abstract available.

PMID:
29871507
7.

Fulfilling the Promise of Unique Device Identifiers.

Dhruva SS, Ross JS, Schulz WL, Krumholz HM.

Ann Intern Med. 2018 Jun 5. doi: 10.7326/M18-0526. [Epub ahead of print] No abstract available.

PMID:
29868760
8.

Network Optimization And The Continuity Of Physicians In Medicaid Managed Care.

Ndumele CD, Staiger B, Ross JS, Schlesinger MJ.

Health Aff (Millwood). 2018 Jun;37(6):929-935. doi: 10.1377/hlthaff.2017.1410.

PMID:
29863934
9.

Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials.

O'Connor JM, Fessele KL, Steiner J, Seidl-Rathkopf K, Carson KR, Nussbaum NC, Yin ES, Adelson KB, Presley CJ, Chiang AC, Ross JS, Abernethy AP, Gross CP.

JAMA Oncol. 2018 May 10:e180798. doi: 10.1001/jamaoncol.2018.0798. [Epub ahead of print]

PMID:
29800974
10.

Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis.

Wallach JD, Egilman AC, Dhruva SS, McCarthy ME, Miller JE, Woloshin S, Schwartz LM, Ross JS.

BMJ. 2018 May 24;361:k2031. doi: 10.1136/bmj.k2031.

11.

Review of clinical trial settings of drugs commonly used in primary care and approved between 2005 and 2012.

Crossley JR, Tan TP, Smith KH, Ross JS, Merenstein DJ.

J Gen Intern Med. 2018 May 18. doi: 10.1007/s11606-018-4486-7. [Epub ahead of print] No abstract available.

PMID:
29777429
12.

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Jimenez Aguilar E, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV.

Cancer Discov. 2018 May 17. pii: CD-18-0099. doi: 10.1158/2159-8290.CD-18-0099. [Epub ahead of print]

PMID:
29773717
13.

Publication and Dissemination of Results in Clinical Trials of Neurology.

Sreekrishnan A, Mampre D, Ormseth C, Miyares L, Leasure A, Ross JS, Sheth KN.

JAMA Neurol. 2018 Apr 30. doi: 10.1001/jamaneurol.2018.0674. [Epub ahead of print] No abstract available.

PMID:
29710083
14.

The Impact of Off-Patent Drug Acquisitions on Prices.

Gupta R, Henkel A, Forman HP, Ross JS.

J Gen Intern Med. 2018 Apr 23. doi: 10.1007/s11606-018-4372-3. [Epub ahead of print] No abstract available.

PMID:
29687433
15.

Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens.

Severson EA, Riedlinger GM, Connelly CF, Vergilio JA, Goldfinger M, Ramkissoon S, Frampton GM, Ross JS, Fratella-Calabrese A, Gay L, Ali S, Miller V, Elvin J, Hadigol M, Hirshfield KM, Rodriguez-Rodriguez L, Ganesan S, Khiabanian H.

Blood. 2018 May 31;131(22):2501-2505. doi: 10.1182/blood-2018-03-840629. Epub 2018 Apr 20. No abstract available.

PMID:
29678827
16.

Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma.

de Velasco G, Wankowicz SA, Madison R, Ali SM, Norton C, Duquette A, Ross JS, Bossé D, Lalani AA, Miller VA, Stephens PJ, Young L, Hakimi AA, Signoretti S, Pal SK, Choueiri TK.

Br J Cancer. 2018 May;118(9):1238-1242. doi: 10.1038/s41416-018-0064-3. Epub 2018 Apr 20.

PMID:
29674707
17.

Older Drugs with Infantile Evidence: The Illustrative Example of Loop Diuretics.

Bikdeli B, Testani JM, Ross JS, Krumholz HM.

Eur Heart J Qual Care Clin Outcomes. 2018 Mar 29. doi: 10.1093/ehjqcco/qcy012. [Epub ahead of print] No abstract available.

PMID:
29617967
18.

Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers.

Pozdeyev N, Gay LM, Sokol ES, Hartmaier R, Deaver KE, Davis S, French JD, Borre PV, LaBarbera DV, Tan AC, Schweppe RE, Fishbein L, Ross JS, Haugen BR, Bowles DW.

Clin Cancer Res. 2018 Apr 3. doi: 10.1158/1078-0432.CCR-18-0373. [Epub ahead of print]

PMID:
29615459
19.

National Prescribing Trends for High-Risk Anticholinergic Medications in Older Adults.

Rhee TG, Choi YC, Ouellet GM, Ross JS.

J Am Geriatr Soc. 2018 Mar 26. doi: 10.1111/jgs.15357. [Epub ahead of print]

PMID:
29582410
20.

Myeloid cell leukemia-1 protein expression and myeloid cell leukemia-1 gene amplification in non small cell lung cancer.

El Jabbour T, Dalvi SD, Kim S, Sheehan C, Ross JS.

Indian J Pathol Microbiol. 2018 Jan-Mar;61(1):27-30. doi: 10.4103/IJPM.IJPM_731_16.

21.

Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study.

Wallach JD, Ciani O, Pease AM, Gonsalves GS, Krumholz HM, Taylor RS, Ross JS.

BMC Med. 2018 Mar 21;16(1):45. doi: 10.1186/s12916-018-1023-9.

22.

Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib.

Carneiro BA, Pamarthy S, Shah AN, Sagar V, Unno K, Han H, Yang XJ, Costa RB, Nagy RJ, Lanman RB, Kuzel TM, Ross JS, Gay L, Elvin JA, Ali SM, Cristofanilli M, Chae YK, Giles FJ, Abdulkadir SA.

Clin Cancer Res. 2018 Jun 15;24(12):2732-2739. doi: 10.1158/1078-0432.CCR-18-0332. Epub 2018 Mar 20.

PMID:
29559559
23.

Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.

Gupta R, Bollyky TJ, Cohen M, Ross JS, Kesselheim AS.

BMJ. 2018 Mar 19;360:k831. doi: 10.1136/bmj.k831.

24.

Highly Resolved Measurements of a Developing Strong Collisional Plasma Shock.

Rinderknecht HG, Park HS, Ross JS, Amendt PA, Higginson DP, Wilks SC, Haberberger D, Katz J, Froula DH, Hoffman NM, Kagan G, Keenan BD, Vold EL.

Phys Rev Lett. 2018 Mar 2;120(9):095001. doi: 10.1103/PhysRevLett.120.095001.

PMID:
29547332
25.

Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing.

Suh JH, Schrock AB, Johnson A, Lipson D, Gay LM, Ramkissoon S, Vergilio JA, Elvin JA, Shakir A, Ruehlman P, Reckamp KL, Ou SI, Ross JS, Stephens PJ, Miller VA, Ali SM.

Oncologist. 2018 Mar 14. pii: theoncologist.2017-0493. doi: 10.1634/theoncologist.2017-0493. [Epub ahead of print]

PMID:
29540602
26.

Gabapentin Approvals, Off-Label Use, and Lessons for Postmarketing Evaluation Efforts.

Wallach JD, Ross JS.

JAMA. 2018 Feb 27;319(8):776-778. doi: 10.1001/jama.2017.21897. No abstract available.

PMID:
29486013
27.

Direct-to-Consumer Broadcast Advertisements for Pharmaceuticals: Off-Label Promotion and Adherence to FDA Guidelines.

Klara K, Kim J, Ross JS.

J Gen Intern Med. 2018 May;33(5):651-658. doi: 10.1007/s11606-017-4274-9. Epub 2018 Feb 26.

PMID:
29484575
28.

Biomedical journal speed and efficiency: a cross-sectional pilot survey of author experiences.

Wallach JD, Egilman AC, Gopal AD, Swami N, Krumholz HM, Ross JS.

Res Integr Peer Rev. 2018 Jan 5;3:1. doi: 10.1186/s41073-017-0045-8. eCollection 2018.

29.

Laboratory evidence of dynamo amplification of magnetic fields in a turbulent plasma.

Tzeferacos P, Rigby A, Bott AFA, Bell AR, Bingham R, Casner A, Cattaneo F, Churazov EM, Emig J, Fiuza F, Forest CB, Foster J, Graziani C, Katz J, Koenig M, Li CK, Meinecke J, Petrasso R, Park HS, Remington BA, Ross JS, Ryu D, Ryutov D, White TG, Reville B, Miniati F, Schekochihin AA, Lamb DQ, Froula DH, Gregori G.

Nat Commun. 2018 Feb 9;9(1):591. doi: 10.1038/s41467-018-02953-2.

30.

A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal.

Sun JX, He Y, Sanford E, Montesion M, Frampton GM, Vignot S, Soria JC, Ross JS, Miller VA, Stephens PJ, Lipson D, Yelensky R.

PLoS Comput Biol. 2018 Feb 7;14(2):e1005965. doi: 10.1371/journal.pcbi.1005965. eCollection 2018 Feb.

31.

Factors Associated With Postmarketing Research for Approved Indications for Novel Medicines Approved by Both the FDA and EMA Between 2005 and 2010: A Multivariable Analysis.

Zeitoun JD, Ross JS, Atal I, Vivot A, Downing NS, Baron G, Ravaud P.

Clin Pharmacol Ther. 2018 Jan 29. doi: 10.1002/cpt.1038. [Epub ahead of print]

PMID:
29377075
32.

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

Lin JJ, Zhu VW, Yoda S, Yeap BY, Schrock AB, Dagogo-Jack I, Jessop NA, Jiang GY, Le LP, Gowen K, Stephens PJ, Ross JS, Ali SM, Miller VA, Johnson ML, Lovly CM, Hata AN, Gainor JF, Iafrate AJ, Shaw AT, Ou SI.

J Clin Oncol. 2018 Apr 20;36(12):1199-1206. doi: 10.1200/JCO.2017.76.2294. Epub 2018 Jan 26.

PMID:
29373100
33.

Bringing Vioxx back to market.

Ross JS, Krumholz HM.

BMJ. 2018 Jan 25;360:k242. doi: 10.1136/bmj.k242. No abstract available.

PMID:
29371221
34.

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.

Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Tejpar S, Sartore-Bianchi A, Hechtman JF, Christiansen J, Novara L, Tebbutt N, Fucà G, Antoniotti C, Kim ST, Murphy D, Berenato R, Morano F, Sun J, Min B, Stephens PJ, Chen M, Lazzari L, Miller VA, Shoemaker R, Amatu A, Milione M, Ross JS, Siena S, Bardelli A, Ali SM, Falcone A, de Braud F, Cremolini C.

J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx089.

PMID:
29370427
35.

Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus.

Schrock AB, Pavlick D, Klempner SJ, Chung JH, Forcier B, Welsh A, Young L, Leyland-Jones B, Bordoni R, Carvajal RD, Chao J, Kurzrock R, Sicklick JK, Ross JS, Stephens PJ, Devoe C, Braiteh F, Ali SM, Miller VA.

Clin Cancer Res. 2018 Apr 15;24(8):1881-1890. doi: 10.1158/1078-0432.CCR-17-3103. Epub 2018 Jan 23.

PMID:
29363525
36.

Statewide Inferior Vena Cava Filter Placement, Complications, and Retrievals: Epidemiology and Recent Trends.

Charalel RA, Durack JC, Mao J, Ross JS, Meltzer AJ, Sedrakyan A.

Med Care. 2018 Mar;56(3):260-265. doi: 10.1097/MLR.0000000000000867.

PMID:
29356721
37.

Medicare Spending and Potential Savings on Brand-Name Drugs With Available Generic Substitutes Excluded by 2 Large Pharmacy Benefit Managers, 2012 Through 2015.

Egilman AC, Wallach JD, Ross JS, Dhruva SS.

JAMA Intern Med. 2018 Apr 1;178(4):567-569. doi: 10.1001/jamainternmed.2017.8016. No abstract available.

PMID:
29340562
38.

Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.

Ross JS, Fakih M, Ali SM, Elvin JA, Schrock AB, Suh J, Vergilio JA, Ramkissoon S, Severson E, Daniel S, Fabrizio D, Frampton G, Sun J, Miller VA, Stephens PJ, Gay LM.

Cancer. 2018 Apr 1;124(7):1358-1373. doi: 10.1002/cncr.31125. Epub 2018 Jan 16.

39.

BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy.

Gornstein EL, Sandefur S, Chung JH, Gay LM, Holmes O, Erlich RL, Soman S, Martin LK, Rose AV, Stephens PJ, Ross JS, Miller VA, Ali SM, Blau S.

Clin Breast Cancer. 2018 Apr;18(2):184-188. doi: 10.1016/j.clbc.2017.12.010. Epub 2017 Dec 21. No abstract available.

PMID:
29325860
40.

Variation in the Diagnosis of Aspiration Pneumonia and Association with Hospital Pneumonia Outcomes.

Lindenauer PK, Strait KM, Grady JN, Ngo CK, Parisi ML, Metersky M, Ross JS, Bernheim SM, Dorsey K.

Ann Am Thorac Soc. 2018 May;15(5):562-569. doi: 10.1513/AnnalsATS.201709-728OC.

PMID:
29298090
41.

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study.

Scagliotti GV, Shuster D, Orlov S, von Pawel J, Shepherd FA, Ross JS, Wang Q, Schwartz B, Akerley W.

J Thorac Oncol. 2018 Jun;13(6):849-854. doi: 10.1016/j.jtho.2017.12.009. Epub 2017 Dec 27.

PMID:
29288764
42.

Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study.

Zeitoun JD, Ross JS, Atal I, Vivot A, Downing NS, Baron G, Ravaud P.

BMJ Open. 2017 Dec 21;7(12):e018587. doi: 10.1136/bmjopen-2017-018587.

43.

Defining Multiple Chronic Conditions for Quality Measurement.

Drye EE, Altaf FK, Lipska KJ, Spatz ES, Montague JA, Bao H, Parzynski CS, Ross JS, Bernheim SM, Krumholz HM, Lin Z.

Med Care. 2018 Feb;56(2):193-201. doi: 10.1097/MLR.0000000000000853.

PMID:
29271820
44.

Data Sharing and Cardiology: Platforms and Possibilities.

Dey P, Ross JS, Ritchie JD, Desai NR, Bhavnani SP, Krumholz HM.

J Am Coll Cardiol. 2017 Dec 19;70(24):3018-3025. doi: 10.1016/j.jacc.2017.10.037. Review.

PMID:
29241491
45.

New and incremental FDA black box warnings from 2008 to 2015.

Solotke MT, Dhruva SS, Downing NS, Shah ND, Ross JS.

Expert Opin Drug Saf. 2018 Feb;17(2):117-123. doi: 10.1080/14740338.2018.1415323. Epub 2017 Dec 17.

PMID:
29215916
46.

Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies.

Miller JE, Wilenzick M, Ritcey N, Ross JS, Mello MM.

BMJ Open. 2017 Dec 5;7(12):e017917. doi: 10.1136/bmjopen-2017-017917.

47.

Collaborative Multi-institutional Experience in Comparing PD-L1 Immunohistochemistry Assays: Concordance of SP142 and 22C3 Immunoreactivity.

Abdul Karim L, Kallakury BVS, Chahine JJ, Sheehan CE, Ross JS.

Appl Immunohistochem Mol Morphol. 2018 Feb;26(2):e22. doi: 10.1097/PAI.0000000000000609. No abstract available.

PMID:
29189261
48.

Physician Denial of Inappropriate Patient Requests-What If I Say No??

Ross JS.

JAMA Intern Med. 2018 Jan 1;178(1):92. doi: 10.1001/jamainternmed.2017.7367. No abstract available.

PMID:
29181540
49.

BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.

Johnson DB, Childress MA, Chalmers ZR, Frampton GM, Ali SM, Rubinstein SM, Fabrizio D, Ross JS, Balasubramanian S, Miller VA, Stephens PJ, Sosman JA, Lovly CM.

Pigment Cell Melanoma Res. 2018 May;31(3):432-436. doi: 10.1111/pcmr.12674. Epub 2017 Dec 16.

50.

Reply to Genomic profiles of nasopharyngeal carcinoma: The importance of histological subtyping and Epstein-Barr virus in situ assays.

Ali SM, Ross JS, Wang K.

Cancer. 2018 Jan 15;124(2):435-436. doi: 10.1002/cncr.31132. Epub 2017 Nov 22. No abstract available.

PMID:
29165787

Supplemental Content

Support Center